GSK shelled out another strong quarter. The CER growth of 4% was galvanised by a 7% FX tailwind, translating into sales of £6.5bn, coming in ahead of our expectation. NB all sales growth numbers are at CER unless specified otherwise. The Pharmaceutical business grew by 2%, vaccines by 11% and the Consumer Healthcare division by 7%. The new products – HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro, Incruse, Nucala) and meningitis vaccines (Menveo, Bexsero) – generate
07 Sep 2016
FX-feat and HIV beat Street expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FX-feat and HIV beat Street expectations
GSK plc (GSK:LON) | 1,709 0 0.0% | Mkt Cap: 70,819m
- Published:
07 Sep 2016 -
Author:
Kamla Singh -
Pages:
3
GSK shelled out another strong quarter. The CER growth of 4% was galvanised by a 7% FX tailwind, translating into sales of £6.5bn, coming in ahead of our expectation. NB all sales growth numbers are at CER unless specified otherwise. The Pharmaceutical business grew by 2%, vaccines by 11% and the Consumer Healthcare division by 7%. The new products – HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro, Incruse, Nucala) and meningitis vaccines (Menveo, Bexsero) – generate